Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ISCP
The International Society of Cardiovascular Pharmacotherapy was created to support and promote ethical, evidence-based, cardiovascular pharmacotherapy worldwide. ISCP represents an ideal forum for open discussions on all issues related to cardiovascular pharmacotherapy and the society endeavours to foster collaboration among health professionals around the World. ISCP promotes education, research… View more
Obesity, Pharmacokinetics and Cardiovascular Drugs
Author(s): Dario Pitocco , Martina Cortelletti , Giovanna Petrucci , et al Added: 1 week ago

Prevention & Chronic Conditions

Anticoagulation
Cardiovascular Effects of NSAIDs: A Review With a Focus on RA Patients
Author(s): Eirik Ikdahl , Anne Kerola , Eli Sollerud , et al Added: 1 year ago

Prevention & Chronic Conditions
Between the Sessions with Dr Parwani: VESALIUS-CV, KARDINAL, CHIP-BCIS3 & M
Author(s): Purvi Parwani Added: 2 months ago
Dr Purvi Parwani (Loma Linda University Health, US) recaps the standout science from Day 2 of ACC 2026, a day defined by a central theme: challenging long-held assumptions in cardiology. Her summary focuses on what these updates mean for day-to-day clinical practice, from prevention strategies to interventional decision-making.Prevention and Risk ReductionVESALIUS-CV: Showed a 25% reduction in… View more

Intervention

Prevention & Chronic Conditions
AHA 25 Late-breaking Discussion: The VESALIUS-CV Trial
Author(s): Erin A Bohula , Harriette Van Spall Added: 6 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9… View more

MI/ACS

Prevention & Chronic Conditions
Levosimendan in Cardiogenic Shock
Author(s): Hendri Susilo , Fan Maitri Aldian , Citrawati Dyah Kencono Wungu , et al Added: 1 year ago

MI/ACS
REDUCE-IT: CV Outcomes With Icosapent Ethyl by Baseline LDL-C
Author(s): Deepak L Bhatt Added: 1 year ago
In this insightful interview, Dr Deepak Bhatt (Mount Sinai Hospital, US) joins us to discuss findings from a post-hoc analysis of the REDUCE-IT trial, examining how icosapent ethyl affects cardiovascular outcomes across different baseline LDL-C levels.The study included 8,175 statin-treated patients with elevated cardiovascular risk and triglyceride levels between 135-499mg/dL. All participants… View more

Prevention & Chronic Conditions
3 ACC.26 Highlights for the Cardiology Pharmacist
Author(s): Craig Beavers Added: 2 months ago
ACC 2026 — In this ISCP-partnered highlights video, Dr Craig Beavers (University of Kentucky College of Pharmacy, Lexington, KY, USA) brings a clinical pharmacist's perspective to ACC.26, spotlighting the three developments most relevant to cardiology pharmacists and the expanding role of pharmacy in cardiovascular care.Produced in collaboration with the International Society of Cardiovascular… View more

Electrophysiology & Arrhythmia

Heart Failure